1. bookVolume 22 (2014): Edizione 1 (March 2014)
Dettagli della rivista
License
Formato
Rivista
eISSN
2284-5623
ISSN
2284-5623
Prima pubblicazione
08 Aug 2013
Frequenza di pubblicazione
4 volte all'anno
Lingue
Inglese
access type Accesso libero

Plasma levels of resistin predict cardiovascular events

Pubblicato online: 25 Mar 2014
Volume & Edizione: Volume 22 (2014) - Edizione 1 (March 2014)
Pagine: 35 - 47
Dettagli della rivista
License
Formato
Rivista
eISSN
2284-5623
ISSN
2284-5623
Prima pubblicazione
08 Aug 2013
Frequenza di pubblicazione
4 volte all'anno
Lingue
Inglese
Abstract

Background: A number of cytokines and adipokines secreted by adipose tissue may influence vessel wall directly. Adiponectin exhibits anti-inflammatory and atheroprotective actions. Resistin is expressed at higher levels in inflammatory cells. Resistin directly activates the endothelium through upreglation of adhesion molecules, induces production of TNF-α by macrophages, effects that are antagonized by adiponectin. Leptin has multiple effects on cells of artery walls, many similar to those of resistin. The prognostic role of adipokines in atherosclerosis is not well established. Methods: We compared the baseline plasma levels of adiponectin, resistin, leptin and TNF-α (ELISA assays) in 59 patients with coronary artery disease (CAD) and 32 patients with peripheral artery disease (PAD). Also, we investigated the impact of baseline plasma levels of adiponectin, resistin, leptin and TNF-α on the incidence of the new ischemic cardiovascular events. Results: In patients with CAD, as compared with PAD, baseline plasma levels of leptin were significantly increased (2882.02 ± 368.57pg/ml vs 1025.56 ± 232.28 pg/ml; p<0.001), plasma levels of resistin were significantly decreased (13.15 ± 0.83ng/ml vs 17.76 ± 2.13 ng/ml; p = 0.02) and no differences in plasma levels of adiponectin and TNF-α were found. A significant correlation between BMI and plasma levels was found only for leptin, irrespective of group. 45 patients (49.5%) were re-hospitalized in a 2 years period of follow-up. In a backward stepwise multivariable Cox regression analysis only resistin ≥ 15 ng/ ml, HR =1.8829, 95% CI 1.0490- 3.3797, p = 0.034 and diastolic blood pressure ≥ 85 mmHg, HR =2.0927, 95%CI 1.0782- 4.0616, p=0.0299 were associated with new cardiovascular events. Conclussion: In patients with clinical atherosclerosis plasma levels of resistin predict new ischemc events.

Keywords

Cuvinte cheie

1. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al. The hormone resistin links obesity to diabetes. Nature. 2001;409(6818):307-12. DOI: 10.1038/3505300010.1038/3505300011201732Search in Google Scholar

2. Wang H, Chu WS, Hemphill C, Elbein SC. Human resistin gene: molecular scanning and evaluation of association with insulin sensitivity and type 2 diabetes in Caucasians. J Clin Endocrinol Metab. 2002;87(6):2520-4. DOI: 10.1210/jcem.87.6.8528 DOI: 10.1210/ jc.87.6.252010.1210/jcem.87.6.852812050208Search in Google Scholar

3. Adeghate E. An update on the biology and physiology of resistin. Cell Mol Life Sci. 2004;61(19-20):2485-96. DOI: 10.1007/s00018-004-4083-210.1007/s00018-004-4083-215526156Search in Google Scholar

4. Stumvoll M, Haring H. Resistin and adiponectin--of mice and men. Obes Res. 2002;10(11):1197-9. DOI: 10.1038/oby.2002.16210.1038/oby.2002.16212429885Search in Google Scholar

5. Vendrell J, Broch M, Vilarrasa N, Molina A, Gomez JM, Gutierrez C, et al. Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. Obes Res. 2004;12(6):962-71. DOI: 10.1038/ oby.2004.11810.1038/oby.2004.11815229336Search in Google Scholar

6. Milan G, Granzotto M, Scarda A, Calcagno A, Pagano C, Federspil G, et al. Resistin and adiponectin expression in visceral fat of obese rats: effect of weight loss. Obes Res. 2002;10(11):1095-103. DOI: 10.1038/ oby.2002.14910.1038/oby.2002.14912429872Search in Google Scholar

7. Silswal N, Singh AK, Aruna B, Mukhopadhyay S, Ghosh S, Ehtesham NZ. Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway. Biochem Biophys Res Commun. 2005;334(4):1092-101. DOI: 10.1016/j.bbrc.2005.06.20210.1016/j.bbrc.2005.06.20216039994Search in Google Scholar

8. Barnes KM, Miner JL. Role of resistin in insulin sensitivity in rodents and humans. Curr Prot Peptide Sci. 2009;10(1):96-107. DOI: 10.2174/13892030978731523910.2174/13892030978731523919275676Search in Google Scholar

9. Kaser S, Kaser A, Sandhofer A, Ebenbichler CF, Tilg H, Patsch JR. Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun. 2003;309(2):286-90. DOI: 10.1016/j.bbrc.2003.07.00310.1016/j.bbrc.2003.07.00312951047Search in Google Scholar

10. Verma S, Li SH, Wang CH, Fedak PW, Li RK, Weisel RD, et al. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation. 2003;108(6):736-40. DOI: 10.1161/01. CIR.0000084503.91330.49Search in Google Scholar

11. Steppan CM, Lazar MA. The current biology of resistin. J Intern Med. 2004;255(4):439-47. DOI: 10.1111/j.1365-2796.2004.01306.x10.1111/j.1365-2796.2004.01306.x15049878Search in Google Scholar

12. Azuma K, Katsukawa F, Oguchi S, Murata M, Yamazaki H, Shimada A, et al. Correlation between serum resistin level and adiposity in obese individuals. Obes Res. 2003;11(8):997-1001. DOI: 10.1038/oby.2003.13710.1038/oby.2003.13712917505Search in Google Scholar

13. de Luis DA, Gonzalez Sagrado M, Conde R, Aller R, Izaola O, Perez Castrillon JL, et al. Relation of resistin levels with cardiovascular risk factors and insulin resistance in non-diabetes obese patients. Diabetes Res Clin Prac. 2009;84(2):174-8. DOI: 10.1016/j.diabres. 2009.01.017Search in Google Scholar

14. Pfutzner A, Langenfeld M, Kunt T, Lobig M, Forst T. Evaluation of human resistin assays with serum from patients with type 2 diabetes and different degrees of insulin resistance. Clin Lab. 2003;49(11-12):571-6.Search in Google Scholar

15. Iqbal N, Seshadri P, Stern L, Loh J, Kundu S, Jafar T, et al. Serum resistin is not associated with obesity or insulin resistance in humans. Eur Rev Med Pharmacol Sci. 2005;9(3):161-5.Search in Google Scholar

16. Chen CC, Li TC, Li CI, Liu CS, Wang HJ, Lin CC. Serum resistin level among healthy subjects: relationship to anthropometric and metabolic parameters. Metabolism. 2005;54(4):471-5. DOI: 10.1016/j.metabol. 2004.10.015Search in Google Scholar

17. Pischon T, Bamberger CM, Kratzsch J, Zyriax BC, Algenstaedt P, Boeing H, et al. Association of plasma resistin levels with coronary heart disease in women. Obes Res. 2005;13(10):1764-71. DOI: 10.1038/ oby.2005.21510.1038/oby.2005.21516286524Search in Google Scholar

18. Chen C, Jiang J, Lu JM, Chai H, Wang X, Lin PH, et al. Resistin decreases expression of endothelial nitric oxide synthase through oxidative stress in human coronary artery endothelial cells. Am J Physiol Hear Cir Physiol. 2010;299(1):H193-201. DOI: 10.1152/ ajpheart.00431.200910.1152/ajpheart.00431.2009290413820435848Search in Google Scholar

19. Kougias P, Chai H, Lin PH, Lumsden AB, Yao Q, Chen C. Adipocyte-derived cytokine resistin causes endothelial dysfunction of porcine coronary arteries. J Vasc Surg. 2005;41(4):691-8. DOI: 10.1016/j. jvs.2004.12.046Search in Google Scholar

20. Burnett MS, Lee CW, Kinnaird TD, Stabile E, Durrani S, Dullum MK, et al. The potential role of resistin in atherogenesis. Atherosclerosis. 2005;182(2):241-8. DOI: 10.1016/j.atherosclerosis.2005.02.01410.1016/j.atherosclerosis.2005.02.01416159596Search in Google Scholar

21. Xu W, Yu L, Zhou W, Luo M. Resistin increases lipid accumulation and CD36 expression in human macrophages. Biochem Biophys Res Commun. 2006;351(2):376-82. DOI: 10.1016/j.bbrc.2006.10.05110.1016/j.bbrc.2006.10.05117067553Search in Google Scholar

22. Rizkalla J, Melone M, Zhao A, Rashid S. The pathophysiological role of resistin in impaired lipoprotein metabolism in obesity. Circulation. 2009;120:S529.Search in Google Scholar

23. Calabro P, Samudio I, Willerson JT, Yeh ET. Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation. 2004;110(21):3335-40. DOI: 10.1161/01. CIR.0000147825.97879.E7Search in Google Scholar

24. Cohen G, Horl WH. Resistin as a cardiovascular and atherosclerotic risk factor and uremic toxin. Semin Dial. 2009;22(4):373-7. DOI: 10.1111/j.1525-139X.2009.00583.x10.1111/j.1525-139X.2009.00583.x19708984Search in Google Scholar

25. Kawanami D, Maemura K, Takeda N, Harada T, Nojiri T, Imai Y, et al. Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun. 2004;314(2):415-9. DOI: 10.1016/j.bbrc.2003.12.10410.1016/j.bbrc.2003.12.10414733921Search in Google Scholar

26. Sharma R, Kumar C, Gangwani S, Singh Sugga G, Rana AC. Resistin and cardiovascular disorder. Afr J of Pharm Pharmacol. 2011;5(1):5.10.1111/j.2042-7158.1986.tb14234.xSearch in Google Scholar

27. Lee TS, Lin CY, Tsai JY, Wu YL, Su KH, Lu KY, et al. Resistin increases lipid accumulation by affecting class A scavenger receptor, CD36 and ATP-binding cassette transporter-A1 in macrophages. Life Sci. 2009;84(3-4):97-104. DOI: 10.1016/j.lfs.2008.11.00410.1016/j.lfs.2008.11.00419041881Search in Google Scholar

28. Li L, Han JL, Mao JM, Guo LJ, Gao W. Association between serum resistin level and cardiovascular events in postmenopausal women with acute coronary syndrome undergoing percutaneous coronary intervention. Clin Med J. 2013;126(6):1058-62.Search in Google Scholar

29. Erer HB, Sayar N, Guvenc TS, Aksaray S, Yilmaz H, Altay S, et al. Prognostic value of serum resistin levels in patients with acute coronary syndrome. Kardiol Pol. 2014;72(2):181-6. DOI: 10.5603/KP.a2013.008610.5603/KP.a2013.008623633273Search in Google Scholar

30. Rosner B. Fundamentals of biostatistics. 5th ed. Pacific Grove, CA: Duxbury; 2000.Search in Google Scholar

31. Zhang MH, Na B, Schiller NB, Whooley MA. Association of resistin with heart failure and mortality in patients with stable coronary heart disease: data from the heart and Soul study. J Card Fail. 2011;17(1):24-30. DOI: 10.1016/j.cardfail.2010.08.00710.1016/j.cardfail.2010.08.00721187261Search in Google Scholar

32. Anfossi G, Russo I, Doronzo G, Pomero A, Trovati M. Adipocytokines in atherothrombosis: focus on platelets and vascular smooth muscle cells. Mediators of inflammation. 2010;2010:174341. DOI: 10.1155/2010/17434110.1155/2010/174341290591120652043Search in Google Scholar

33. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, et al. Serum immunoreactive- leptin concentrations in normal-weight and obese humans. N Engl J of Med. 1996;334(5):292-5. DOI: 10.1056/NEJM19960201334050310.1056/NEJM1996020133405038532024Search in Google Scholar

34. Piemonti L, Calori G, Mercalli A, Lattuada G, Monti P, Garancini MP, et al. Fasting plasma leptin, tumor necrosis factor-alpha receptor 2, and monocyte chemoattracting protein 1 concentration in a population of glucose-tolerant and glucose-intolerant women: impact on cardiovascular mortality. Diabetes care. 2003;26(10):2883-9. DOI: 10.2337/diacare.26.10.288310.2337/diacare.26.10.288314514596Search in Google Scholar

35. Scholze A, Rattensperger D, Zidek W, Tepel M. Low serum leptin predicts mortality in patients with chronic kidney disease stage 5. Obesity (Silver Spring). 2007;15(6):1617-22. DOI: 10.1038/oby.2007.19110.1038/oby.2007.19117558000Search in Google Scholar

36. Sattar N, Wannamethee G, Sarwar N, Chernova J, Lawlor DA, Kelly A, et al. Leptin and coronary heart disease: prospective study and systematic review J Am Coll Cardiol. 2009;53(2):167-75. DOI: 10.1016/j. jacc.2008.09.035Search in Google Scholar

37. Ku IA, Farzaneh-Far R, Vittinghoff E, Zhang MH, Na B, Whooley MA. Association of low leptin with cardiovascular events and mortality in patients with stable coronary artery disease: the Heart and Soul Study. Atherosclerosis. 2011;217(2):503-8. DOI: 10.1016/j. atherosclerosis.2010.10.047Search in Google Scholar

38. Owens CD, Kim JM, Hevelone ND, Hamdan A, Raffetto JD, Creager MA, et al. Novel adipokines, high molecular weight adiponectin and resistin, are associated with outcomes following lower extremity revascularization with autogenous vein. J Vasc Surg. 2010;51(5):1152-9. DOI: 10.1016/j.jvs.2009.12.05110.1016/j.jvs.2009.12.051286067320223619Search in Google Scholar

39. Osawa H, Doi Y, Makino H, Ninomiya T, Yonemoto K, Kawamura R, et al. Diabetes and hypertension markedly increased the risk of ischemic stroke associated with high serum resistin concentration in a general Japanese population: the Hisayama Study. Cardiovasc Diabetol. 2009;8:60. DOI: 10.1186/1475-2840-8-6010.1186/1475-2840-8-60279044119922611Search in Google Scholar

40. Rajpathak SN, Kaplan RC, Wassertheil-Smoller S, Cushman M, Rohan TE, McGinn AP, et al. Resistin, but not adiponectin and leptin, is associated with the risk of ischemic stroke among postmenopausal women: results from the Women’s Health Initiative. Stroke. 2011;42(7):1813-20. DOI: 10.1161/STROKEAHA. 110.607853Search in Google Scholar

41. Zhang MH, Na B, Schiller NB, Whooley MA. Resistin, exercise capacity, and inducible ischemia in patients with stable coronary heart disease: data from the Heart and Soul study. Atherosclerosis. 2010;213(2):604-10. DOI: 10.1016/j.atherosclerosis.2010.09.01510.1016/j.atherosclerosis.2010.09.01520951381Search in Google Scholar

42. Krecki R, Krzeminska-Pakula M, Peruga JZ, Szczesniak P, Lipiec P, Wierzbowska-Drabik K, et al. Elevated resistin opposed to adiponectin or angiogenin plasma levels as a strong, independent predictive factor for the occurrence of major adverse cardiac and cerebrovascular events in patients with stable multivessel coronary artery disease over 1-year follow-up. Med Sci Monit. 2011;17(1):CR26-32. DOI: 10.12659/MSM.88132510.12659/MSM.881325352468121169907Search in Google Scholar

43. Lubos E, Messow CM, Schnabel R, Rupprecht HJ, Espinola-Klein C, Bickel C, et al. Resistin, acute coronary syndrome and prognosis results from the Athero- Gene study. Atherosclerosis. 2007;193(1):121-8. DOI: 10.1016/j.atherosclerosis.2006.05.03910.1016/j.atherosclerosis.2006.05.03916814296Search in Google Scholar

44. Lee SH, Ha JW, Kim JS, Choi EY, Park S, Kang SM, et al. Plasma adiponectin and resistin levels as predictors of mortality in patients with acute myocardial infarction: data from infarction prognosis study registry. Coron Artery Dis. 2009;20(1):33-9. DOI: 10.1097/ MCA.0b013e328318ecb010.1097/MCA.0b013e328318ecb018997620Search in Google Scholar

45. Efstathiou SP, Tsiakou AG, Tsioulos DI, Panagiotou TN, Pefanis AV, Achimastos AD, et al. Prognostic significance of plasma resistin levels in patients with atherothrombotic ischemic stroke. Clin Chim Acta. 2007;378(1-2):78-85. DOI: 10.1016/j.cca.2006.10.02310.1016/j.cca.2006.10.02317173885Search in Google Scholar

46. Pilz S, Weihrauch G, Seelhorst U, Wellnitz B, Winkelmann BR, Boehm BO, et al. Implications of resistin plasma levels in subjects undergoing coronary angiography. Clin Endocrinol. 2007;66(3):380-6. DOI: 10.1111/j.1365-2265.2007.02743.x10.1111/j.1365-2265.2007.02743.x17302872Search in Google Scholar

47. Hoefle G, Saely CH, Risch L, Koch L, Schmid F, Rein P, et al. Relationship between the adipose-tissue hormone resistin and coronary artery disease. Clin Chim Acta. 2007;386(1-2):1-6. DOI: 10.1016/j.cca.2007.07.00110.1016/j.cca.2007.07.00117706624Search in Google Scholar

48. Luc G, Empana JP, Morange P, Juhan-Vague I, Arveiler D, Ferrieres J, et al. Adipocytokines and the risk of coronary heart disease in healthy middle aged men: the PRIME Study. Int J Obes (Lond). 2010;34(1):118-26. DOI: 10.1038/ijo.2009.20410.1038/ijo.2009.20419823188Search in Google Scholar

49. Lim S, Koo BK, Cho SW, Kihara S, Funahashi T, Cho YM, et al. Association of adiponectin and resistin with cardiovascular events in Korean patients with type 2 diabetes: the Korean atherosclerosis study (KAS): a 42-month prospective study. Atherosclerosis. 2008;196(1):398-404. DOI: 10.1016/j.atherosclerosis. 2006.11.017 Search in Google Scholar

Articoli consigliati da Trend MD

Pianifica la tua conferenza remota con Sciendo